

## TREATMENT FORM



Date\*:

**INSTRUCTIONS** 

To be completed in full, signed, and dated, then faxed to 844-394-7155. For additional assistance, call 84-INGREZZA (844-647-3992), 8  $_{\rm AM}$  - 8  $_{\rm PM}$  EST, M - F.

1 PATIENT INFORMATION									
irst Name*: Last Name*:				Last 4 digits of	f the SSN:		Date of Birth*: / /		
Address:			City:		Sta	State: ZIP:			
Preferred Phone:			US Resident:	☐ Yes ☐	No Ge	nder: 🗆 N	Лale	☐ Fem	iale
Is Preferred Phone a Mobile Number?			Email:						
Alternate Contact/Care Partner Name:			Alternate Contact/Care Partner Phone:						
Patient Residence: At Home LTC Group Home Other (Optional) I consent to have my prescription shipped to: Care Partner HCP office									
Patient/Authorized Representative Signature:		Date:							
By signing here, I authorize the use and disclosure of my PHI as set forth in the HIPAA Authorization on page 3.  Description of Authorized Representative's Authority:									
2 PATIENT INSURANCE INF	a copy of the patient's insurance card (check below if no insurance)								
Medical Insurance Name:			Prescription Insurance Name:						
Cardholder ID #:			Cardholder ID #:						
Policy Holder Name:			BIN#:			PCN#:			
Phone: Policy Holder DOB: / /			Rx Group #:			Phone:			
Payer Type:  Commercial Medicare Medicaid Other Patient does not have insurance									
3 CLINICAL INFORMATION									
Primary Diagnosis Code Category*:     Tardiv	on's chorea (G10)	n's chorea (G10)							
4 PRESCRIPTION FOR INGREZZA (valbenazine) CAPSULES									
PRESCRIPTION INSTRUCTIONS*: Check one Rx box below.									
Initial Rx with 80 mg Maintenance Rx  40 mg once daily x 7 then	60 mg Maintenance Rx Only <sup>a</sup> 60 mg once daily  80 mg Maintenance Rx Only <sup>a</sup> 80 mg once daily								
80 mg once daily x 23 No refills.  1-month supply. Refills # OR 1-month supply.									s #
80 mg once daily 1-month supply. <b>Refills #</b>									
Other Rx Sig:	Quantity: Other Rx Refills:								
<sup>a</sup> lf 40 mg in-office samples were used, you may choose t	o select 60 mg or 80 n	ng Maintenance Rx C	nly.		[bA +ro	atment form is	not required	if a proce	rintion
Preferred Pharmacy   [Amber Specialty Pharmacy]   [Orsini Specialty Pharmacy]   [PANTHERX Rare]   [Same to a Walgreens Community-Based Specialty Pharmacy]   [AllianceRx Walgreens Pharmacy]   No Preference   No Preference   Panther Specialty Pharmacy   Pharmacy - please contact the store directly.]									
5 PRESCRIBER INFORMATION	N								
Prescriber Name*:			Prescriber NPI*:						
Facility Name:				Phone:			Fax:		
Address: City:			State:		ZIP:				
Office/Facility Contact Name: Phone:		Fax:		Email:					
6 PRESCRIBER CERTIFICATION	NC								
I certify that the information provided in this INGREZZ/judgment of medical necessity, and I will supervise the to share identifiable information with Neurocrine Bios Section 4 above. I authorize the forwarding of this pres I agree not to receive any compensation for dispensing	patient's medical trea ciences, Inc., its agent scription and informa	atment. I certify that s and pharmacies, i tion to a dispensing	, where required by nocluding but not limi specialty pharmacy.	federal and/or stat ted to the INBRACI If the patient has r	e law, I have E Support Pro	obtained my pa gram Pharmac	itient's writte y and the ph	n legal pe armacies	ermission listed in

(Original signature required—If required by applicable law, please attach copies of all prescriptions on official state prescription forms) \*Indicates required fields.



Prescriber or Authorized Agent Signature: \*



## TREATMENT FORM



## PATIENT HIPAA AUTHORIZATION FOR USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION

I authorize Neurocrine, companies working with Neurocrine, my healthcare provider and pharmacy to use and disclose to Neurocrine, and companies working with Neurocrine, my Protected Health Information ("PHI"), such as information provided on the INGREZZA Treatment Form, my prescription, insurance, medical therapy information and other PHI for the following purposes: (1) providing financial assistance options, (2) reimbursement support, (3) medication compliance and persistence, (4) information about Neurocrine products and programs, which may from time to time include requests to participate in market research or other initiatives related to my experiences with Tardive Dyskinesia and/or INGREZZA, and (5) other treatment-related services, including providing information and materials related to the INBRACE Support Program (collectively called "Support Services"). I authorize the disclosure of my PHI to communicate with the Alternate Contact/Care Partner listed in Section 1 of the Treatment Form. I understand that the companies working with Neurocrine, including my pharmacy, may receive payment for the use and disclosure of my PHI. I understand that once it is disclosed, it may be re-disclosed by the recipient(s). After such a disclosure, the information may no longer be protected by HIPAA or the terms of this authorization against further re-disclosure. I understand that this authorization shall continue in effect for a period of ten years unless a shorter period is required by law. I understand that I may revoke this authorization to use or disclose my PHI by contacting an INBRACE Support Program representative by telephone (844-647-3992) or by mailing a letter to Neurocrine, Attn: INBRACE Support Program, 12780 El Camino Real, San Diego, CA 92130. I understand that my healthcare provider, pharmacy, and/or Neurocrine will not condition my treatment on signing this Authorization. I can choose not to sign this Authorization. However, if I choose not to sign, Neurocrine will not be able to help me with Support Services as described above. I may obtain a copy of this Authorization upon request.

For the Neurocrine Biosciences, Inc. Privacy Policy, please visit www.neurocrine.com/about-us/privacy-policy/

